These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30825700)

  • 1. Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?
    Escolà-Vergé L; Larrosa N; Los-Arcos I; Viñado B; González-López JJ; Pigrau C; Almirante B; Len O
    J Glob Antimicrob Resist; 2019 Dec; 19():28-31. PubMed ID: 30825700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Labombardi VJ; Rojtman A; Tran K
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):313-5. PubMed ID: 17084784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.
    Song W; Moland ES; Hanson ND; Lewis JS; Jorgensen JH; Thomson KS
    J Clin Microbiol; 2005 Sep; 43(9):4891-4. PubMed ID: 16145169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Outbreak of ESBL-producing Klebsiella pneumoniae in an Iranian Referral Hospital: Epidemiology and Molecular Typing.
    Mahmoudi S; Pourakbari B; Rahbarimanesh A; Abdosalehi MR; Ghadiri K; Mamishi S
    Infect Disord Drug Targets; 2019; 19(1):46-54. PubMed ID: 29732983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
    Marra AR; Pereira CA; Castelo A; do Carmo Filho JR; Cal RG; Sader HS; Wey SB
    Int J Infect Dis; 2006 Jan; 10(1):56-60. PubMed ID: 16326126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection.
    Quale JM; Landman D; Bradford PA; Visalli M; Ravishankar J; Flores C; Mayorga D; Vangala K; Adedeji A
    Clin Infect Dis; 2002 Oct; 35(7):834-41. PubMed ID: 12228820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
    Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
    J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum β-lactamase-producing Klebsiella pneumoniae.
    Saely S; Kaye KS; Fairfax MR; Chopra T; Pogue JM
    Am J Infect Control; 2011 Jun; 39(5):390-395. PubMed ID: 21255875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First report of OXA-232-producing Klebsiella pneumoniae strains in Tunisia.
    Lahlaoui H; Bonnin RA; Moussa MB; Khelifa ABH; Naas T
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):195-197. PubMed ID: 28341097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
    Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
    Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
    Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
    Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OXA-48-Like-Producing Klebsiella pneumoniae in Southern Spain in 2014-2015.
    Machuca J; López-Cerero L; Fernández-Cuenca F; Mora-Navas L; Mediavilla-Gradolph C; López-Rodríguez I; Pascual Á
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.